CTI BIOPHARMA CORP Form 8-K December 09, 2014

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

### CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2014 (December 6, 2014)

### CTI BIOPHARMA CORP.

(Exact name of registrant as specified in its charter)

Washington001-1246591-1533912(State or other jurisdiction of(Commission(I.R.S. Employer

incorporation or organization) File Number) Identification Number) 3101 Western Avenue, Suite 600

Seattle, Washington 98121

(Address of principal executive offices)

Registrant's telephone number, including area code: (206) 282-7100

Not applicable

# Edgar Filing: CTI BIOPHARMA CORP - Form 8-K

(Former name or former address, if changed since last report).

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

"Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

"Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

"Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

"Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

# Edgar Filing: CTI BIOPHARMA CORP - Form 8-K

Item 7.01. Regulation FD Disclosure.

On December 6, 2014, CTI BioPharma Corp. (the "Company") issued a press release entitled "CTI BioPharma Announces Comprehensive Kinome Analysis that Demonstrates Pacritinib Inhibits Kinases Linked to a Spectrum of Blood-Related Cancers." The full text of such press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

On December 9, 2014, the Company issued a press release entitled "CTI BioPharma Announces Presentation of Data Demonstrating Pacritinib Overrides Stromal Mediated Resistance in FLT3-ITD Positive AML Cells." The full text of such press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K.

The information provided pursuant to this Item 7.01 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act") or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any filing or other document filed by the Company pursuant to the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document. The information provided pursuant to this Item 7.01 shall instead be deemed "furnished."

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit

No.	Description	Location
99.1	Press Release of CTI BioPharma Corp., dated December 6, 2014.	Furnished herewith.
99.2	Press Release of CTI BioPharma Corp., dated December 9, 2014.	Furnished herewith.

### SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

### CTI BIOPHARMA CORP.

Date: December 9, 2014 By: /s/ Louis A. Bianco Louis A. Bianco Executive Vice President, Finance and Administration

# EXHIBIT INDEX

Exhibit

No.	Description	Location
	Press Release of CTI BioPharma Corp., dated December 6, 2014. Press Release of CTI BioPharma Corp., dated December 9, 2014.	